+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H2 2018

  • ID: 4667856
  • Drug Pipelines
  • November 2018
  • Region: Global
  • 134 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Beta Pharma Inc
  • Eli Lilly and Co
  • G1 Therapeutics Inc
  • MEI Pharma Inc
  • MetaMax Ltd
  • Novartis AG
  • MORE
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H2 2018

Summary

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Cyclin-dependent kinase 4 is an enzyme encoded by the CDK4 gene. Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G1/S transition. Activation of the cyclin-D-CDK4 complex appears to require other factors such as recruitment of the substrate via a substrate recruitment motif, and/or formation of the CDKN1B ternary complex.

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) pipeline Target constitutes close to 23 molecules. Out of which approximately 22 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 5, 3, 9, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Immunology, Metabolic Disorders and Toxicology which include indications Breast Cancer, Metastatic Breast Cancer, Colorectal Cancer, Mantle Cell Lymphoma, Non-Small Cell Lung Cancer, Bladder Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Pancreatic Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Dedifferentiated Liposarcoma, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Leukemias, Liposarcoma, Lymphoma, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Neuroblastoma, Oligodendroglioma, Pancreatic Ductal Adenocarcinoma, Peritoneal Cancer, Recurrent Glioblastoma Multiforme (GBM), Thymic Carcinoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), AIDS - Related Cancer, Anaplastic Oligoastrocytoma, Astrocytoma, Brain Tumor, Cervical Cancer, Chemotherapy Induced Myelosuppression, Chordoma, Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Diffuse Large B-Cell Lymphoma, Ductal Carcinoma In Situ, Duodenal Cancer, Ependymoma, Epithelial Ovarian Cancer, Epstein-Barr Virus (HHV-4) Infections, Ewing Sarcoma, Fallopian Tube Cancer, Follicular Lymphoma, Head And Neck Cancer, High-Grade Glioma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Kidney Cancer (Renal Cell Cancer), Liver Cancer, Lung Cancer, Malignant Mesothelioma, Marginal Zone B-cell Lymphoma, Medulloblastoma, Melanoma, Meningioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Brain Tumor, Metastatic Ovarian Cancer, Metastatic Pancreatic Cancer, Multiple Myeloma (Kahler Disease), Neuroendocrine Tumors, Nonmelanomatous Skin Cancer, Ovarian Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Primary CNS Lymphoma, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Rhabdomyosarcoma, Rheumatoid Arthritis, Small-Cell Lung Cancer, Solid Tumor, Squamous Non-Small Cell Lung Cancer, Type 2 Diabetes and Well Differentiated Liposarcoma.

The latest report Cyclin Dependent Kinase 4 - Pipeline Review, H2 2018, outlays comprehensive information on the Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)
  • The report reviews Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Beta Pharma Inc
  • Eli Lilly and Co
  • G1 Therapeutics Inc
  • MEI Pharma Inc
  • MetaMax Ltd
  • Novartis AG
  • MORE
Introduction

Report Coverage

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Overview

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Companies Involved in Therapeutics Development

Beta Pharma Inc

Eli Lilly and Co

G1 Therapeutics Inc

Jiangsu Hengrui Medicine Co Ltd

MEI Pharma Inc

MetaMax Ltd

Novartis AG

Onconova Therapeutics Inc

Pfizer Inc

Sihuan Pharmaceutical Holdings Group Ltd

Sino Biopharmaceutical Ltd

Teijin Pharma Ltd

Tiziana Life Sciences Plc

ViroStatics srl

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Drug Profiles

abemaciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BEBT-209 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BPI-1178 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GZ-381 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HEC-80797 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lerociclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

milciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MMD-37K - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ON-123300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palbociclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ribociclib succinate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHR-6390 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK 4 and 6 for Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK1, CDK4 and CDK6 for Colorectal Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK4 and CDK6 for Colorectal Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK4 and CDK6 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRX-3177 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TQ-05510 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trilaciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

voruciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VS.-2370 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XZP-3287 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Dormant Products

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Discontinued Products

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Product Development Milestones

Featured News & Press Releases

Nov 01, 2018: MEI Pharma to present preclinical data of Voruciclib in combination with Venetoclax at ASH 2018

Oct 23, 2018: Targeted drug could extend lives of some women with advanced breast cancer

Oct 22, 2018: Pfizer’s palbociclib increases overall survival in breast cancer patients

Oct 21, 2018: G1 Therapeutics presents additional data from randomized phase 2 trial of Trilaciclib in combination with Etoposide/Carboplatin for treatment of first-line small cell lung cancer

Oct 16, 2018: Tiziana Life Sciences presents data from animal studies demonstrating the potential synergistic activity of Milciclib with tyrosine kinase inhibitors to treat Hepatocellular Carcinoma (HCC) at the American Association for the Study of Liver Diseases (AASLD)

Oct 09, 2018: G1 Therapeutics to present additional data from randomized phase 2 trial of Trilaciclib in combination with Etoposide/Carboplatin at European Society for Medical Oncology (ESMO) 2018 Congress

Oct 03, 2018: EU nod for Lilly’s new breast cancer drug

Sep 17, 2018: G1 Therapeutics to report Myelopreservation data from randomized phase 2 trial of Trilaciclib/Chemotherapy/Tecentriq in Small Cell Lung Cancer in Fourth Quarter 2018

Sep 13, 2018: G1 Therapeutics announces appointment of Garry Nicholson to Board of Directors

Aug 07, 2018: Pfizer's breakthrough innovative drug IBRANCE (palbociclib) receives approval in China

Jul 26, 2018: Lilly receives CHMP's positive opinion for Verzenios

Jul 18, 2018: FDA approves expanded indication for Novartis drug Kisqali

Jul 09, 2018: TRIO Awarded NATALEE Study, Largest Single Phase III Breast Cancer Clinical Trial in its History

Jun 25, 2018: Pfizer unveils new results from PALOMA-3 trial for breast cancer

Jun 04, 2018: Results from AstraZeneca Study Presented at ASCO

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..3), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Companies, H2 2018 (Contd..4), H2 2018

Products under Development by Companies, H2 2018 (Contd..5), H2 2018

Products under Development by Companies, H2 2018 (Contd..6), H2 2018

Products under Development by Companies, H2 2018 (Contd..7), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Beta Pharma Inc, H2 2018

Pipeline by Eli Lilly and Co, H2 2018

Pipeline by G1 Therapeutics Inc, H2 2018

Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2018

Pipeline by MEI Pharma Inc, H2 2018

Pipeline by MetaMax Ltd, H2 2018

Pipeline by Novartis AG, H2 2018

Pipeline by Onconova Therapeutics Inc, H2 2018

Pipeline by Pfizer Inc, H2 2018

Pipeline by Sihuan Pharmaceutical Holdings Group Ltd, H2 2018

Pipeline by Sino Biopharmaceutical Ltd, H2 2018

Pipeline by Teijin Pharma Ltd, H2 2018

Pipeline by Tiziana Life Sciences Plc, H2 2018

Pipeline by ViroStatics srl, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Dormant Products, H2 2018 (Contd..2), H2 2018

Discontinued Products, H2 2018

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Beta Pharma Inc
  • Eli Lilly and Co
  • G1 Therapeutics Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • MEI Pharma Inc
  • MetaMax Ltd
  • Novartis AG
  • Onconova Therapeutics Inc
  • Pfizer Inc
  • Sihuan Pharmaceutical Holdings Group Ltd
  • Sino Biopharmaceutical Ltd
  • Teijin Pharma Ltd
  • Tiziana Life Sciences Plc
  • ViroStatics srl
Note: Product cover images may vary from those shown
Adroll
adroll